Exo Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $77.8M

  • Investors
  • 12

Exo Therapeutics General Information

Description

Developer of a small-molecule therapeutics platform designed to target exosites and distal binding pockets that modulate enzyme activity for precise and potent therapeutic effects. The company's platform leverages a confluence of technologies that allow for seeing, modeling, building, designing, and discovering exosite-targeted small molecule drugs and can be applied across enzyme classes to discover therapeutic candidates across diseases, enabling healthcare institutions to expand the diversity of targets.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 150 Cambridge Park Drive
  • Suite 300
  • Cambridge, MA 02140
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 150 Cambridge Park Drive
  • Suite 300
  • Cambridge, MA 02140
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 04-Oct-2021 $77.8M Completed Clinical Trials - General
2. Early Stage VC (Series A) 16-Dec-2020 Completed Clinical Trials - General
1. Accelerator/Incubator Completed Startup
To view Exo Therapeutics’s complete valuation and funding history, request access »

Exo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Exo Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Exo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a small-molecule therapeutics platform designed to target exosites and distal binding pockets that modulate
Drug Discovery
Cambridge, MA
17 As of 2026

Boulder, CO
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exo Therapeutics Competitors (3)

One of Exo Therapeutics’s 3 competitors is Edgewise Therapeutics, a Formerly VC-backed company based in Boulder, CO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Edgewise Therapeutics Formerly VC-backed Boulder, CO
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
BioCryst Pharmaceuticals Corporation Durham, NC
You’re viewing 3 of 3 competitors. Get the full list »

Exo Therapeutics Patents

Exo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021195183-A1 Compositions and methods for inhibiting protein embryonic ectoderm development activity and treating disease Inactive 24-Mar-2020

Exo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exo Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
120 Capital Venture Capital Minority
BVF Partners Hedge Fund Minority
Casdin Capital Venture Capital Minority
Morningside Group Venture Capital Minority
Nextech Invest Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Exo Therapeutics FAQs

  • When was Exo Therapeutics founded?

    Exo Therapeutics was founded in 2018.

  • Where is Exo Therapeutics headquartered?

    Exo Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Exo Therapeutics?

    Exo Therapeutics has 17 total employees.

  • What industry is Exo Therapeutics in?

    Exo Therapeutics’s primary industry is Drug Discovery.

  • Is Exo Therapeutics a private or public company?

    Exo Therapeutics is a Private company.

  • What is the current valuation of Exo Therapeutics?

    The current valuation of Exo Therapeutics is .

  • What is Exo Therapeutics’s current revenue?

    The current revenue for Exo Therapeutics is .

  • How much funding has Exo Therapeutics raised over time?

    Exo Therapeutics has raised $103M.

  • Who are Exo Therapeutics’s investors?

    120 Capital, BVF Partners, Casdin Capital, Morningside Group, and Nextech Invest are 5 of 12 investors who have invested in Exo Therapeutics.

  • Who are Exo Therapeutics’s competitors?

    Edgewise Therapeutics, Sarepta Therapeutics, and BioCryst Pharmaceuticals are competitors of Exo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process